Press Releases

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/476754/pipeline_insight) has announced the addition of the "Pipeline Insight: Colorectal Cancer - Growing Trend Towards Personalized Medicine" report to their offering.

CRC incidence will be over 490,000 cases by 2018 in the seven major markets. This large patient base will translate into a high commercial potential for the development of novel, more effective therapies. Currently, there are 77 agents in development for CRC, 4 of which are in late-phase development. Collectively, they are forecast to achieve sales of $1,398m by 2018.

Scope

    --  Examination of the CRC pipeline with in-depth clinical and commercial
        profiles of Phase III candidates
    --  Seven major pharmaceutical market sales forecasts for Phase III pipeline
        products through to 2018
    --  Segmentation and analysis of the current CRC pipeline by developmental
        phase, drug class and company
    --  Insight and analysis of market potential including commercial
        opportunity, epidemiology and discussion of unmet needs

Highlights of this title

    --  The CRC pipeline consists of 77 drugs, of which 60% are molecular
        targeted therapies (MTTs), 22% are immunotherapies, and 17% are
        cytotoxic therapies. MTTs constitute the bulk of the CRC pipeline. This
        is in line with R&D in other tumor types, where there is a shift away
        from standard cytotoxic therapies towards MTTs and personalized
        medicine.
    --  The late-phase CRC pipeline consists only of MTTs. Except for one agent;
        all the others are being investigated in previously-treated patients.
        Drug developers appear to be pursuing approval for treatment in the
        second-line setting where barriers to market entry are lower and the
        high level of unmet need may facilitate a drug's uptake and approval.
    --  Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis) is forecast to achieve
        the highest level of sales among the late-phase pipeline candidates in
        the CRC market, generating 604m by 2018 in the seven major
        pharmaceutical markets.

Key reasons to purchase this title

    --  Identify key drugs and companies within the CRC pipeline based on sales
        forecasts to 2018 and Datamonitor drug assessment.
    --  Characterize unmet need and poorly served patient subsets within the CRC
        market and assess the potential for pipeline products to fulfil them.
    --  Segmentation and analysis of the current CRC pipeline by developmental
        phase, drug class, company and indication.

Key Topics Covered:

Executive Summary

    --  Strategic scoping and focus
    --  Datamonitor insight into the colorectal cancer market
    --  Datamonitor pipeline assessment summary
    --  Related reports
    --  Upcoming related reports

Pipeline Overview and dynamics

    --  Key findings
    --  Pipeline overview
    --  Pipeline summary
    --  Novel molecular targeted therapies dominate the current late-phase
        colorectal cancer pipeline
    --  Comparative forecasts
    --  Datamonitor pipeline assessment summary
    --  Key companies involved in the colorectal cancer (CRC) pipeline
    --  Amgen
    --  AstraZeneca
    --  Roche
    --  Key R&D company strategies
    --  Ongoing shift towards molecular targeted therapies in colorectal cancer
    --  Line extensions of already marketed drugs

Colorectal cancer - Market Potential

    --  Colorectal cancer is one of the 'big four' tumors and numbers are set to
        rise over the next decade
    --  Histology
    --  Risk factors
    --  CRC is predominantly a disease of the elderly
    --  People with CRC in the family have a high risk of developing the disease
    --  Western style diets contribute to CRC incidence
    --  Rise of CRC in the migrant population
    --  Symptoms
    --  Screening and diagnosis
    --  Fecal occult blood test is the most commonly used screening method
    --  Endoscopic methods are not ideal for CRC screening
    --  CRC screening remains fragmented between countries
    --  Patient segmentation
    --  Proper staging is essential to the design of treatment plans
    --  Epidemiology
    --  Seven major markets
    --  CRC cases are expected to rise in line with the aging world population
    --  Low detection in the early stages of the disease results in a high
        mortality rate
    --  Rest of the world
    --  Current treatment options
    --  Surgery remains the primary treatment choice for early-stage CRC
    --  Adjuvant therapy extends disease-free survival in Stage III patients
    --  Combination chemotherapy is the standard of care in metastatic disease
    --  Avastin is used predominantly in the US in the first-line setting
    --  Erbitux is indicated for use in patients with wild-type KRAS status
    --  Vectibix has limited uptake in the treatment of the disease
    --  Current comparator therapy
    --  Eloxatin (oxaliplatin; Sanofi-aventis)
    --  Unmet need in colorectal cancer (CRC)
    --  Better screening approaches needed to decrease mortality rates
    --  There is a need for more effective therapies in both early-stage and
        advanced disease
    --  Biomarkers and the selection of patients may help improve outcomes
    --  Target product profile versus current level of attainment

R&D Approach

    --  Key findings
    --  Clinical trial design in colorectal cancer (CRC)
    --  Patient selection
    --  Clinical trial endpoints in oncology
    --  Overall survival
    --  Disease-free survival
    --  Overall response rates
    --  Progression-free survival
    --  Disease control
    --  Toxicity

Pipeline Analysis & Forecasts: Molecular Targeted Therapies

    --  Key findings
    --  Overview of the molecular targeted therapies
    --  Pipeline summary

Innovative Early-Stage Approaches

    --  Key findings
    --  Overview of early-stage innovative projects
    --  TRAIL
    --  Insulin-like growth factor receptor (IGFR)
    --  MAP kinase pathway
    --  The future of treatment of colorectal cancer (CRC)
    --  Molecular markers will become an important part of therapy for patient
        selection
    --  The future will see more combination therapies to target multiple
        pathways
    --  Increased understanding of cancer evolution should result in a large
        range of potential drug targets
    --  Bibliography
    --  Journals
    --  Websites

APPENDIX

Companies Mentioned:

    --  AstraZeneca PLC
    --  Biogen Idec, Inc.
    --  Boehringer Ingelheim GmbH
    --  Bristol-Myers Squibb Company
    --  Eli Lilly and Company
    --  Genentech, Inc.
    --  Human Genome Sciences, Inc.
    --  IMS Health
    --  Keryx Biopharmaceuticals, Inc.
    --  Merck KGaA
    --  Schering-Plough Corporation

For more information visit http://www.researchandmarkets.com/research/476754/pipeline_insight

Source: Datamonitor

    Source: Research and Markets

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Just a year after its August 2008 debut on Florida's Gold Coast, The Ritz-Carlton, Fort Lauderdale was tapped as AAA's only choice for its prestigious Five Diamond award, leading the Fort Lauderdale hotel segment in the quest to become Florida's newest luxury vacation destination.

"The Ladies and Gentlemen of The Ritz-Carlton, Fort Lauderdale are extremely honored to receive this prestigious symbol of excellence, especially in this challenging economy," said General Manager, Jim Oliver. "We are proud of our continued commitment to personalized service that creates unparalleled experiences and lifelong memories for our guests."

Located oceanfront at One Fort Lauderdale Beach Boulevard, the 24-story, dramatically tiered, glass walled hotel has sweeping curves reminiscent of a grand luxury liner. Design elements recall elegant 1940's travel, with artwork that includes playful murals inspired by French artist Jean Cocteau and a 13-foot seascape mural inspired by the 1880 painting, "King Neptune and His Horses." The property features 192 guest rooms and suites (all with water views); 24,000 square feet of light-filled meeting space; a raised 29,000 square foot ocean view tropical sundeck with an infinity pool and private cabanas, a large water-view fitness center and the city's only luxury spa, an 8,000 square foot oasis with a 99 percent organic menu and several light-infused treatment rooms. Dining and entertainment options include Cero, the three-meal-a-day restaurant with seating indoors or al fresco on an ocean-view terrace, a picturesque oceanfront Lobby Bar, a dramatic Wine Room with a 5,000 bottle wine cellar and a seventh floor Pool Bar with commanding ocean views.

Guests at The Ritz-Carlton, Fort Lauderdale will appreciate the myriad opportunities outside the hotel's door, including water sports, shopping, a water taxi along the "Venice of the West," and exclusive access to the private, members-only Grande Oaks Golf Club. Families will appreciate the Kid's Meal Plan, which allows children under 12 the ability to dine for just $30 per day - a tremendous value. Overnight packages include the Resort Reconnect, which offers luxurious accommodations, daily American breakfast for two in Cero restaurant and a $50 resort credit from $309 per night through December 31, 2009, and the Sand and Sun package from $269 per night with resort credit based on length of stay.

For reservations, please phone 954-465-2300, toll-free: 800-241-3333 or visit www.ritzcarlton.com.

    Source: The Ritz-Carlton

MCLEAN, Va. and SAN DIEGO, Nov. 11 /PRNewswire-FirstCall/ -- Science Applications International Corporation (SAIC) (NYSE: SAI) today announced that its wholly owned design-build subsidiary Benham has received the Design-Build Institute of America (DBIA) 2009 National Excellence Award for the design and construction of the Boral Bricks manufacturing plant in Terre Haute, Ind.

Boral is the largest manufacturer of and distributor of clay brick in the United States, and the 295,000-square-foot Indiana plant is the largest brick manufacturing facility in the U.S. DBIA is an association of leaders in the design and construction industry utilizing design-build and integrated project delivery methods to achieve high performance projects. The award was presented at the DBIA's 2009 Conference and Expo in Washington, D.C.

"DBIA's recognition and the fact that we were able to achieve LEED® Silver Certification for the largest brick plant in the United States are testaments to our project team's commitment to excellence and innovation, SAIC's corporate commitment to a sustainable future, and the strong creative business relationship between Boral and Benham," said J.T. Grumski, SAIC senior vice president and business unit general manager.

The U.S. Green Building Council's LEED, or Leadership in Energy and Environmental Design, is the nation's leading program for the certification of green buildings.

About SAIC

SAIC is a FORTUNE 500(® )scientific, engineering, and technology applications company that uses its deep domain knowledge to solve problems of vital importance to the nation and the world, in national security, energy and the environment, critical infrastructure, and health. The company's approximately 45,000 employees serve customers in the U.S. Department of Defense, the intelligence community, the U.S. Department of Homeland Security, other U.S. Government civil agencies and selected commercial markets. Headquartered in McLean, Va., SAIC had annual revenues of $10.1 billion for its fiscal year ended January 31, 2009. For more information, visit www.saic.com. SAIC: From Science to Solutions(®)

Statements in this announcement, other than historical data and information, constitute forward-looking statements that involve risks and uncertainties. A number of factors could cause our actual results, performance, achievements, or industry results to be very different from the results, performance, or achievements expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to, the risk factors set forth in SAIC's Annual Report on Form 10-K for the period ended January 31, 2009, and other such filings that SAIC makes with the SEC from time to time. Due to such uncertainties and risks, readers are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date hereof.

    Contact:     Melissa Koskovich                 Laura Luke
                 (703) 676-6762                    (703) 676-6533
                 melissa.l.koskovich@saic.com      laura.luke@saic.com

SOURCE SAIC

KEW GARDENS, N.Y., Nov. 11 /PRNewswire/ -- When parents and grandparents pick out holiday gifts for children, they want to feel good about their decisions, and in a tough economy, they are even more selective about toy purchases. Moreover, the safety of many children's accessories and toys made in China remain in question. Just this week, for example, stroller-maker Maclaren announced a recall affecting one million China-manufactured umbrella strollers that reportedly can injure children's fingers. Shoppers seeking safe alternatives turn to NMCtoys.com (http://www.NMCtoys.com), a retail website that's devoted to quality toys made in the United States.

"It's not just parents - grandparents, too, have become very conscientious consumers," says Kerry Menger, co-founder of NMCtoys.com. "They're researching their options, and choosing us because they want safe, eco-friendly toys and educational gifts for their grandchildren. They also love how our products are 'Made in the USA.' There's no doubt that the sales that come from these goods stimulate the health of our domestic economy. That's the icing on the cake."

NMCtoys.com debuted in 2007 in response to the mass recalls of "Made in China" toys that took place that year. The online resource was a hit - and its owners predict greater success this holiday season, considering recent updates and a broader mission. NMCtoys.com has an expanded product line, a larger offering of "green" toys, and a goal to support U.S.-based toy manufacturers. With many options in both entertaining and educational toys, parents and grandparents feel this website is an ideal resource for various reasons.

"I have a special needs grandson (toddler), and am particularly interested in toys designed for young children who have both physical and mental challenges," says Lauren, one customer who now receives the website's coupon- and product-packed newsletter.

Another customer, Teresa, is regularly using NMCtoys.com's gift certificates to purchase baby shower gifts. Now she has a grandson and shops the website because she trusts the quality of its toys, even if she spends a little more for this peace of mind.

"I've been saying for so long that people want everything to be so cheap and are not willing to spend money for quality merchandise, which is why we have all this substandard junk being imported," Teresa says.

Some products must be ordered 21 days in advance, so NMCtoys.com recommends placing holiday orders soon.

About NMCtoys.com

As the parents of two small children, Kerry and Andrew Menger founded NMCtoys.com, a retail website providing safe, high-quality toys. As part of their mission, they only carry children's toys that are not "Made in China."

Many toys sold at NMCtoys.com have received awards, and all meet or exceed U.S. safety standards. NMCtoys.com pledges that its toys will last - and are designed to foster children's imagination, improve motor skills and bolster self-esteem.

For more information, visit http://www.nmctoys.com.

    Contact:

    Kerry Menger
    President, NMCtoys.com
    1-877-622-8697
    kerry@nmctoys.com

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com.

SOURCE NMCtoys.com

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/b1ac26/general_motors_cor) has announced the addition of the "General Motors Corporation: Corporate Analysis" company profile to their offering.

This company profile is a premium company information product offering an unmatched depth and breadth of content. It analyzes the strategic positioning of the company - how the company has evolved and how it has been performing over the years.

Sectional Highlights:

    --  Structure of the organization, partnerships, mergers & acquisitions and
        recent developments have been examined
    --  Business segments of the company have been explored along with analysis
        of key products and services
    --  SWOT Analysis highlights the weaknesses of the company and the threats
        to which it is exposed; the strengths of the company and the way the
        company has positioned itself to take advantage of the opportunities
    --  Business and marketing strategies boosting earnings, brand value and
        competitive edge have been discussed
    --  Key financial indicators have been analyzed
    --  Competitive positioning of the company has been evaluated in terms of
        sales, profitability and stock performance, as compared to its
        competitors

Key Benefits:

    --  Provides input for strategic business planning
    --  Targets business opportunities & risks
    --  Exploits competitive intelligence

Target Audience:

    --  Investment Managers
    --  Venture Capitalists
    --  Management Consultants
    --  Research Companies
    --  Other Industry Professionals

Key Topics Covered:

Company Backgrounder

    --  Corporate Overview
    --  Key Facts
    --  Corporate Timeline

Business Focus

    --  Major Segments
    --  Products & Services

Corporate Overview

    --  Organizational Structure
    --  Executive Biographies
    --  Ownership Structure
    --  Subsidiaries
    --  Key Partnerships
    --  Mergers & Acquisitions
    --  Significant Developments

Strategic Analysis

    --  SWOT
    --  Strategic Focus

Financial Analysis

    --  Financial Performance
    --  Sales and Earnings Analysis
    --  Ratio Analysis
    --  Stock Performance

Competitor Analysis

    --  Major Competitors
    --  Peer Comparison at a Glance
    --  Financial Comparison
    --  Stock Chart

Company Outlook

    --  Revenue & Income Estimates

For more information visit http://www.researchandmarkets.com/research/b1ac26/general_motors_cor

    Source: Research and Markets